Literature DB >> 24624536

A comparison of FDA and EMA drug approval: implications for drug development and cost of care.

Lynn J Howie, Bradford R Hirsch, Amy P Abernethy.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24624536

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  4 in total

1.  A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.

Authors:  Minette-Joëlle Zeukeng; Enrique Seoane-Vazquez; Pascal Bonnabry
Journal:  Eur J Clin Pharmacol       Date:  2018-02-22       Impact factor: 2.953

Review 2.  Fast-track drug approval in inflammatory bowel diseases.

Authors:  Konstantinos H Katsanos; Efstratios Koutroumpakis; Eftychia Giagkou; Zikos Malakos; Eleni Almpani; Alexandros Skamnelos; Dimitrios K Christodoulou
Journal:  Ann Gastroenterol       Date:  2016-06-03

Review 3.  Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Authors:  Toon van der Gronde; Carin A Uyl-de Groot; Toine Pieters
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

4.  A comprehensive CHO SWATH-MS spectral library for robust quantitative profiling of 10,000 proteins.

Authors:  Kae Hwan Sim; Lillian Chia-Yi Liu; Hwee Tong Tan; Kelly Tan; Daniel Ng; Wei Zhang; Yuansheng Yang; Stephen Tate; Xuezhi Bi
Journal:  Sci Data       Date:  2020-08-11       Impact factor: 6.444
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.